

Uncovering the saliency of local topological features for Alzheimer's disease characterisation

Philip Hartout

November 26, 2020

Alzheimer's disease

Alzheimer's disease: 🧠

Alzheimer's disease

Alzheimer's disease: 

- Nearly 40 million people live with AD

Alzheimer's disease

Alzheimer's disease:

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030

Alzheimer's disease


Alzheimer's disease:

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU

Alzheimer's disease

Alzheimer's disease: 🧠

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU




Alzheimer's disease

Alzheimer's disease: 🧠

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU


Topology: 🍩 ☕



Alzheimer's disease

Alzheimer's disease: 🧠

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU




Topology: 🍩 ☕

- Concerned with “properties of a geometric object that are preserved under **continuous deformations**, such as [...] crumpling.”

Alzheimer's disease

Alzheimer's disease: 🧠

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU




Topology: 🍩 ☕

- Concerned with “properties of a geometric object that are preserved under **continuous deformations**, such as [...] crumpling.”
- Recently, *persistent homology* has emerged to quantify (differences in) the shape of data.

Alzheimer's disease

Alzheimer's disease: 🧠

- Nearly 40 million people live with AD
- Cost in US alone \$ 2 trillion by 2030
- Among leading causes of death in EU



Topology: 🍩 ☕


- Concerned with “properties of a geometric object that are preserved under **continuous deformations**, such as [...] crumpling.”
- Recently, *persistent homology* has emerged to quantify (differences in) the shape of data.
- **How can we apply persistent homology to quantify changes in shape due to Alzheimer's disease?**

1. Classification

1. **Classification**
2. Subtype identification

1. **Classification**
2. Subtype identification
3. Progression & forecasting

Analysis setting




Unprocessed

Analysis setting



Unprocessed




fMRIPrep


Analysis setting



Unprocessed



fMRIPrep




Patch selection


Analysis setting




Unprocessed



fMRIPrep



Patch selection




Persistence homology


Analysis setting




Unprocessed




fMRIPrep



Patch selection




Persistence homology



Persistence Image

Analysis setting



Analysis setting





Figure 2: AUPRC on each patch, achieved using a model described in earlier work. Chosen patch for analyses is boxed in red (patch with highest accuracy).


I - Persistent homology

CN


H_0



H_1




H_2




AD


H_0




H_1



H_2




I - Classification - Persistence Images




I - Classification - Network architecture

Persistence image (H_0, H_1, H_2)


I - Classification - Network architecture




I - Classification - Network architecture




I - Classification - Network architecture




I - Classification - Network architecture




I - Classification - Network architecture



I - Classification - Network architecture



I - Classification - Network architecture



Methodological considerations

- 4 fold CV, 3 inits. Stratified for age, diagnoses and no patients are spread over folds.
- Same experimental settings as from Brüningk, Sarah C *et al*
<https://arxiv.org/abs/2011.06531>

I - Classification - Performance

Local Global	PI	3D Conv	PI
Validation accuracy	0.79 ± 0.02	0.85 ± 0.06	0.76 ± 0.02
Precision	0.81 ± 0.04	0.87 ± 0.04	0.74 ± 0.02
Recall	0.81 ± 0.02	0.87 ± 0.08	0.88 ± 0.08
AUC	0.85 ± 0.03	0.89 ± 0.05	0.78 ± 0.02

Table 1: Performance metrics of the different models trained on the same data.

Metrics from Brüningk, Sarah C *et al* <https://arxiv.org/abs/2011.06531>.

I - Classification - Performance

Local Global	PI	3D Conv	PI
Validation accuracy	0.79 ± 0.02	0.85 ± 0.06	0.76 ± 0.02
Precision	0.81 ± 0.04	0.87 ± 0.04	0.74 ± 0.02
Recall	0.81 ± 0.02	0.87 ± 0.08	0.88 ± 0.08
AUC	0.85 ± 0.03	0.89 ± 0.05	0.78 ± 0.02

Table 1: Performance metrics of the different models trained on the same data.

Metrics from Brüningk, Sarah C *et al* <https://arxiv.org/abs/2011.06531>.

→ Local PI training time is 2 minutes on a **laptop CPU**. Very efficient compression of features!

→ Local 3D Conv training takes 15 minutes on a **server GPU**.

I - Classification - Performance

Local Global	PI	3D Conv	PI
Validation accuracy	0.79 ± 0.02	0.85 ± 0.06	0.76 ± 0.02
Precision	0.81 ± 0.04	0.87 ± 0.04	0.74 ± 0.02
Recall	0.81 ± 0.02	0.87 ± 0.08	0.88 ± 0.08
AUC	0.85 ± 0.03	0.89 ± 0.05	0.78 ± 0.02

Table 1: Performance metrics of the different models trained on the same data.

Metrics from Brüningk, Sarah C *et al* <https://arxiv.org/abs/2011.06531>.

→ Local PI training time is 2 minutes on a **laptop CPU**. Very efficient compression of features!

→ Local 3D Conv training takes 15 minutes on a **server GPU**.

Persistent homology produces **highly salient compressed** features for AD characterization.

Limitations:

- Using **raw** images is **better**, but more **expensive**.

Limitations:

- Using **raw** images is **better**, but more **expensive**.
- Does not take atrophy from **other regions** into account

Limitations:

- Using **raw** images is **better**, but more **expensive**.
- Does not take atrophy from **other regions** into account

Future directions:

- Can persistent homology be used to diagnose **prodromal** forms of AD?

Limitations:

- Using **raw** images is **better**, but more **expensive**.
- Does not take atrophy from **other regions** into account

Future directions:

- Can persistent homology be used to diagnose **prodromal** forms of AD?
- Use a similar approach for **subtype identification**.


Thanks!

GitHub repository of the project

`github.com/pjhartout/TDA_ADNI_MLCB`

With thanks to Bastian Rieck for the supervision and Sarah Brueningk, Felix Hensel, Catherine Jutzeler, Merel Kuijs and Louis Lukas for insightful discussions, code, and data.

Questions?



Backup slides

II - Distance analysis among patients in CN, MCI & AD

Median persistence landscape.




Figure 3: CN




Figure 4: MCI




Figure 5: AD

II - Distance analysis among patients in CN, MCI & AD

Question: How topologically heterogenous is the data?

	Mean	Median	Standard deviation	Q3	Max	Skewness
CN H_0	2.16	2.00	0.78	2.50	7.41	1.78
CN H_1	2.61	2.27	1.17	2.93	9.47	1.92
CN H_2	2.38	2.23	0.88	2.79	7.19	1.39
MCI H_0	2.24	2.04	0.82	2.55	6.21	1.71
MCI H_1	2.57	2.19	1.29	2.80	11.87	2.57
MCI H_2	2.40	2.27	0.83	2.82	6.55	1.18
AD H_0	2.40	2.18	0.96	2.77	7.77	1.97
AD H_1	2.47	2.13	1.15	2.77	9.28	2.10
AD H_2	2.36	2.20	0.80	2.75	8.39	1.64

Table 2: Summary statistics of the distribution of distances

III - Distance analysis among patients who deteriorate vs. those who don't

Question: Among the patients who deteriorate, do we see higher average pairwise distances compared to patients who don't deteriorate?

III - Distance analysis among patients who deteriorate vs. those who don't

Question: Among the patients who deteriorate, do we see higher average pairwise distances compared to patients who don't deteriorate?

- The data is a longitudinal dataset (multiple timepoints are available for each patient)

III - Distance analysis among patients who deteriorate vs. those who don't

Question: Among the patients who deteriorate, do we see higher average pairwise distances compared to patients who don't deteriorate?

- The data is a longitudinal dataset (multiple timepoints are available for each patient)
- Some patients deteriorate (transition from CN→MCI or from MCI→AD)

III - Distance analysis among patients who deteriorate vs. those who don't

Question: Among the patients who deteriorate, do we see higher average pairwise distances compared to patients who don't deteriorate?

- The data is a longitudinal dataset (multiple timepoints are available for each patient)
- Some patients deteriorate (transition from CN→MCI or from MCI→AD)
- Compute pairwise distance between patients (L^1 PL distance, Wasserstein distance and bottleneck distance), and average for each patient.

III - Distance analysis among patients who deteriorate vs. those who don't

Example of L^1 norm between PLs of a deteriorating patient.




Figure 6: H_0




Figure 7: H_1




Figure 8: H_2

III - Distance analysis among patients who deteriorate vs. those who don't

Example of L^1 norm between PLs of a subject who does *not* deteriorate.




Figure 9: H_0




Figure 10: H_1




Figure 11: H_2

III - Distance analysis among patients who deteriorate vs. those who don't

Persistence landscape L^1 norm




Figure 12: H_0




Figure 13: H_1




Figure 14: H_2

III - Distance analysis among patients who deteriorate vs. those who don't

Bottleneck L^1 norm




Figure 15: H_0




Figure 16: H_1




Figure 17: H_2

III - Distance analysis among patients who deteriorate vs. those who don't

Wasserstein distance




Figure 18: H_0




Figure 19: H_1




Figure 20: H_2